| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H10FN3S |
| Molecular Weight | 223.27 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N=C(N(C)C1=S)C2=CC(F)=CC=C2
InChI
InChIKey=IWDUZEHNLHFBRZ-UHFFFAOYSA-N
InChI=1S/C10H10FN3S/c1-13-9(12-14(2)10(13)15)7-4-3-5-8(11)6-7/h3-6H,1-2H3
| Molecular Formula | C10H10FN3S |
| Molecular Weight | 223.27 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Suritozole (also known as MDL 26,479) is an aryldialkyltriazolethione derivative patented by Merrell Dow Pharmaceuticals, Inc as an antidepressant. Suritozole acts as negative modulator at the gamma-aminobutyric acid A (GABAA) receptor that enhances cholinergic function. In preclinical models, chronic treatment Suritozole produces a small but significant decrease in the average spontaneous firing rate of Purkinje neurons. Suritozole attenuated a scopolamine-induced acquisition deficit in a T-maze reinforced alternation task, suggesting that the compound may have memory enhancing potential.
